More than 18 million Americans have a depressive disorder, according to the Uplift Program, a depression statistics site. When left untreated, an emotional disorder may lead an individual to substance abuse and addiction. Drug rehab centers can help individuals suffering from addiction, but a new medication may be able to help people suffering from depression.
Recently, Neutralstem Incorporated announced that the U.S. Food and Drug Administration has approved an Investigational New Drug application to begin testing a medication that has the potential to help individuals with severe depression.
NSI-189 is a compound that stimulates the hippocampus, the area of the brain that is responsible for long-term memory. Disruptions in this area have been thought to cause depression and Alzheimer’s disease.
Experts say that antidepressants used to treat patients today are focused on serotonin deficiencies. However, NSI-189 stimulates the hippocampus and encourages new neuron growth, which may help individuals suffering from depression.
Depression will be the second-largest killer alongside heart disease in the U.S. by 2020, according to the Uplift Program. Rehabilitation facilities may be able to help individuals cope with the condition over time.